Targeting this Reelin-LRP8-CDC42 axis with MEN 10207, a neurokinin-2 receptor antagonist, inhibited BC cell migration and reduced BM in zebrafish and mouse models, offering a promising therapeutic strategy. This evidence concerns the gene RELN and breast cancer.